November 13, 2006 -- Merck reported so-so results for a new COX-2 drug called Arcoxia; an Isis drug reduced LDL (bad) cholesterol levels by 62% in a Phase II trial; FavID, a cancer immunotherapeutic from Favrille, missed its secondary endpoint in a Phase III trial; Lilly reported positive results from a Phase III trial of Arxxant for diabetic retinopathy; Dendreon completed filing for approval of Provenge for prostate cancer; ZymoGenetics and Serono reported positive early data for lupus drug atacicept; and Illumina will acquire fellow genetic analysis company Solexa in a $600 million all-stock deal. The Centient Biotech 200™ slipped 9 points lower to 3945, a drop of .24%. More details...
